Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, of the December 29, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased DexCom securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To join the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 29, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4] Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5] - Defendants allegedly overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues, leading to increased regulatory scrutiny and potential legal repercussions [5] - The lawsuit claims that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the true information became public [5]

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased or sold Cepton common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff is required to file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Cepton's management made materially false and misleading statements regarding the company's business and operations [5]. - Specific allegations include the failure to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition and the Board's lack of meaningful exploration of this offer [5]. - As a result, shareholders were deprived of the opportunity to make an informed decision regarding the Koito Acquisition [5].

Core Viewpoint - Rosen Law Firm is urging investors of Perrigo Company plc to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to the company's performance during the specified class period from February 27, 2023, to November 4, 2025 [1]. Group 1: Legal Action Details - Investors who purchased Perrigo securities during the class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by January 16, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, which suffered from significant underinvestment and required substantial capital expenditures [5]. - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow [5]. - The lawsuit asserts that the positive statements made by Perrigo about its business operations were materially misleading and lacked a reasonable basis, resulting in investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is urging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Molina - The lawsuit claims that Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is alleged that Molina's growth was reliant on limited utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that positive statements made by Molina regarding its business and prospects were materially misleading due to the undisclosed adverse facts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked highly for securities class action settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Telix Pharmaceuticals Ltd. to secure legal counsel before the January 9, 2026 deadline for a securities class action lawsuit related to the company's alleged misleading statements during the class period from February 21, 2025, to August 28, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Telix securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by January 9, 2026 [3]. - The lawsuit claims that Telix's management made materially false statements regarding the progress of its prostate cancer therapeutic candidates and the quality of its supply chain, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of the Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Impact - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 30, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for its performance in securities class action settlements [4] Group 3: Case Allegations - The lawsuit alleges that Synopsys' management made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5] - Specific claims include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business and the misleading nature of positive statements made by the defendants [5]

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Sprouts Farmers Market, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SFMDecember 02, 2025 8:16 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - December 2, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities and sellers of put options of Sprouts Farmers Market, Inc. (NASDAQ: SFM) between June 4, 2025 a ...

Michael Nederhoff Joins the Board of Directors of Powermax Minerals Inc.December 02, 2025 7:30 PM EST | Source: Powermax Minerals Inc.Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) (FSE: T23) ("Powermax" or the "Company") wishes to announce a board change, effective immediately, Michael Nederhoff will join the board of directors replacing the Michael Malana. The Company wishes to thank Mr. Malana for his service.Michael Nederhoff has a ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Firefly Aerospace Inc. due to allegations of misleading statements and operational issues that have negatively impacted the company's stock performance and investor confidence [2][5]. Group 1: Company Overview - Firefly Aerospace conducted its initial public offering (IPO) on August 7, 2025, selling 19.296 million shares at a price of $45.00 per share [6]. - The company reported a significant loss of $80.3 million, or $5.78 per share, for Q2 2025, which is an increase from a loss of $58.7 million, or $4.60 per share, in the same quarter of 2024 [7]. - Revenue for Q2 2025 was reported at $15.55 million, falling short of analyst estimates of $17.25 million and representing a 26.2% decrease from the previous year [7]. Group 2: Stock Performance and Market Reaction - Following the Q2 earnings report, Firefly's stock price dropped by $7.58 per share, or 15.31%, closing at $41.94 on September 23, 2025 [8]. - On September 29, 2025, Firefly disclosed a failure in the first stage of its Alpha Flight 7 rocket, leading to further concerns about the company's technology and commercial viability [9]. - This announcement resulted in an additional decline in stock price by $7.66 per share, or 20.73%, closing at $29.30 on September 30, 2025 [10]. Group 3: Legal Proceedings - A federal securities class action has been filed against Firefly, with a deadline of January 12, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Firefly and its executives made false or misleading statements regarding the demand for its Spacecraft Solutions and the operational readiness of its Alpha rocket program [5].